text:
Minneapolis, Minnesota Web Multimedia Schools
Do you want training in Web Multimedia? There are some great Minneapolis web design schools that offer Web Multimedia programs. Stop wasting your time and learn more about how a degree in Web Multimedia can help you in your career.
Learn More About Web Multimedia Campus Schools & Degree Programs in Minneapolis, Minnesota
Matching School Ads
Programs Offered:
- Graphic Design Associates - Web and Interactive Design Specialization
- Graphic Design Associates - Animation and Motion Graphics Specialization
- Graphic Design Bachelors - Web and Interactive Design Specialization
Campus Locations:
Now is a particularly exciting time for media production, but with technology more advanced than it ever was, starting a career in production is challenging without the proper skills.
Programs Offered:
- Associate in Applied Science in Sound Design for Visual Media
- Associate in Applied Science in Digital Video and Media Production
- Bachelor of Fine Arts in Digital Video & Media Production
Campus Locations:
Matching School Ads
Narrow Your Search By City


text: Extreme Grappling Challenge 7 View: Extreme Grappling Challenge 7 - Mixed Martial Arts (MMA) Event on December 7, 2001 in Revere, Massachusetts USA Share: Share on Facebook Share on Twitter Share on Google Plus Post a Comment Fight Winner Loser Method Round Time 1 Mike Lind Chris Kennedy Submission 1 4:12 2 Adailton Reis Whitney Powers TKO/RSC 2 1:40 Mike Lind vs. Chris Kennedy Mike Lind 1-1-0 0 lbs. WINNER Chris Kennedy 8-12-0 6′ 0″ 170 lbs. Submission in the 1st round Adailton Reis vs. Whitney Powers Adailton Reis 2-0-0 0 lbs. WINNER Whitney Powers 0-1-0 0 lbs. TKO/RSC (Referee Stoppage) in the 2nd round

subset: commoncrawl


text: You divide the number of sts you have by three or four depending on how many DPNs you're going to use and then knit that many onto each DPN. So, if you have 40 sts left and want to put them on 4 DPNs (and knit with the 5th) knit 10 sts onto each needle. Hope that helps.


text:
After a bachelor of science in International Finance from ESG Management school (Paris) and Mantissa institute (Kuala Lumpur).
I have decided to pursue an MBA in finance at ESG school and Webber international University (USA).
Since my graduation I have mainly worked for Bnp Paribas securities services for almost five years, especially on UCITS, Stocks, and Forex.
Now I'm the founder of tradewithferl where I share my knowledge and experience with my peers.


text:
18350 Hopewell Road
Mount Venon, OH 43050
On December 4th, 1800 Congress approved the use of the Capitol Building as a church building. Non-denominational public worship was regularly administered at the Capitol each week for their own services. Records show that by 1867, over 2,000 people per week attended church services at the Capitol. The Capitol Building was a public building where the US government met for official government business.
As a radical believer and follower of the Jesus of the Bible, I have often found myself in a dilemma. I want people to see my Savior for who He really is, and yet, I am often embarrassed at how we believers portray Him. Jesus is too often a victim of mistaken identity. He is seen (maybe this is how you see him) as hateful and intolerant. He is seen as a political activist with little or no concern for the heartfelt views of others. He is viewed as only a friend to those that hold His causes in high regard. For this I apologize. I know that the things you might believe are just as important to you as the things I believe are to me.
The founding founders of the American Constitution officially adopted the motto, "In God We Trust." Every American coin and paper currency has these words printed on it, "In God We Trust." And it is not a coincidence that all witnesses who testify in the courts and before Congressional hearings must take an oath and swear to affirm before God that they will tell the truth.


text:
*Free Shipping On Orders Over $75*
Pothos w/Coiled Rope Planter Silk Plant - - - - Green
Handsome is what we'd call this stately Pothos silk plant. With countless lush leaves in several different shades of green, this full Pothos will fool even the most discerning plant lover into thinking it's real. Smartly paired with a beautiful coiled rope planter, this is the ideal ornament for any home or office. Also makes a perfect gift.
Size including pot - Height: 17 inches X Width: 22inches X Depth: 18 inches
Pot size - Width: 7 inches X Height: 7 inches
Color: Green
Customers Also Purchased
Recently Viewed Items
At QualitySilkPlants.com we want you to be thrilled about your purchase and offer a 100% Guarantee. Click here to read more...
Look At Our Newest Videos:
Short videos with home and office decorating ideas and new product showcasing on YouTube.
22" Artificial Sunflower Arrangement in Ceramic Rooster Motif Pot
Price: $69.99
Sale Price: $16.99
12" Artificial Dendrobium Orchid Arrangement
Price: $34.99
Sale Price: $14.99
4" Artificial Aeonium Succulent Cactus Pick
Price: $5.99
Sale Price: $3.79
Set of 2 - 7' Phoenix Palm Silk Trees
Price: $399.99
Sale Price: $259.99
48" Artificial Fig Plant Tree in Clay Container
Price: $199.99
Sale Price: $139.99
Copyright 2004 - 2016 QualitySilkPlants.com All Rights Reserved.
**Free shipping is for the lower 48 U.S. states only. Please see our shipping page for rates to Alaska and Hawaii.
*(cannot be combined with other coupons or promotions)
17" Pothos with Coiled Rope Planter Table Plant


text:
What is JotForm?
JotForm is a free online form builder which helps you create online forms without writing a single line of code. No sign-up required.
At JotForm, we want to make sure that you're getting the online form builder help that you need. Our friendly customer support team is available 24/7.
We believe that if one user has a question, there could be more users who may have the same question. This is why many of our support forum threads are public and available to be searched and viewed. If you'd like help immediately, feel free to search for a similar question, or submit your question or concern.
JotForm Application: Not showing submissionsAsked by Sandy2121 on September 26, 2016 at 10:55 PMAlso- its really tiring that the jotform app sends false notifcations - I have contacted the developer 4 times with no response/result. I have also uninstalled and reinstalled with no luck.
JotForm Support
Can you please tell us which JotForm app you refer to here?
We will check further once we have a better understanding of the issue.
Thank you.
Version 1.5
Droid is what I use it on does that answer your question?
JotForm Support
I tested this issue in our JotForm android application and I was able to replicate the issue.
I will forward this to our developer team for further checking and we'll inform you though this thread about the outcome.
Thank you for your understanding.
JotForm Developer
We have updated our android app. Please install latest version from Google Play Store. After your login you will receive and see your submissions.
Thanks for using JotForm,


text:
- Advertising Aerospace Agriculture Animals/Pets Automotive Biotech Boating Business / economics Chemistry Cities and provinces Comics Computer hardware Computers Construction Countryside Culture and art
- Decoration Education Electronics Energy Engineering Environment and nature Family Finance Food and Beverages Forest and Wood Gardening Government Handicraft Homeland Insurance International
- Legal Leisure Lifestyle Logistics Manufacturing Marketing Media Medical Metal industry and Metallurgy Military Music and Entertainment Non-profit Paper industry Photography Politics Publishing
- Real estate Religion Retail Science Security Site News Social services Software Sport / leisure Sports Telecommunications Topstory Tourism Working life
Home » Releases » Business / economics » Hospitality Sector Best Performer in Stable Abu Dhabi Real Estate Market, According to JLL Q1 2015 Real Estate Market Overview
Hospitality Sector Best Performer in Stable Abu Dhabi Real Estate Market, According to JLL Q1 2015 Real Estate Market Overview
Media release.
Published: 21-Apr-2015 10:37 am
Publisher: Jones Lang LaSalle
JLL, the world's leading real estate investment and advisory firm, today has released its first quarter (Q1 2015) Abu Dhabi Real Estate Overview report that assesses the latest trends in the office, residential, retail and hospitality sectors. The report was released today at Cityscape Abu Dhabi, which is taking place from 21-23 April 2015. JLL is once again leading the Market Overview presentation and panel discussion on the opening day of Cityscape Abu Dhabi.
The first quarter of 2015 recorded further growth in the residential rental and hospitality sectors while the residential sales, retail and office sectors remained stable. Following the decline in oil prices, JLL expects there to be a reduction in government spending this year which will slow down the pace of demand growth – growth is expected to continue, but at a lower rate.. On the other hand, the short-term supply picture is alsorelatively under control leading to generally stable market conditions.
David Dudley, Regional Director and Head of Abu Dhabi Office at JLL MENA, commented: "In the first quarter of 2015, the Abu Dhabi real estate market experienced strong growth in the hospitality sector and further growth of residential rents balanced by further stabilization in the office, residential sales and retail sectors. In contrast to the downward pressure we saw for the hospitality market in Dubai during the quarter, the Abu Dhabi hotel sector saw an increase in hotel ADRs for the first time since 2010 as demand outpaced supply expansion. The growth in hospitality demand is largely driven by a range of ongoing government initiatives to grow tourism demand - including the expansion of Etihad Airways and the Airport, further enhancement of Abu Dhabi's leisure offering, and campaigns by the Abu Dhabi Tourism & Culture Authority to promote Abu Dhabi regionally and globally."
He continued: "Residential demand remains dominated by residents who are interested in renting, rather than buying property. Rental growth for prime residential units continued at 4% during Q1, following 11% growth in 2014 and 17% in 2013, primarily due to limited quality supply across all price points and the removal of the rent cap. While average prime rents increased, the residential sales market remained stable this quarter, following 25% annual growth of prime residential prices over the past two years. The office market remained stable this past quarter, with demand remaining relatively flat and limited new supply entering the market. Overall vacancy rates for office space are expected to remain at this level throughout the year, given the significant proportion of near-term completions that are pre-committed."
He concluded: "Following a two year bull-run, we are currently going through a period of mid-cycle stabilization".
- Office: Total stock reached approximately 3.2 million sq m GLA in Q1, with the Finance House HQ at Capital Centre adding approximately 25,000 sq m GLA. An additional 359,000 sq m of office GLA is expected to be delivered throughout the year including Addax Tower on Reem Island, ADIB HQ on Airport Road and Al Hilal Bank HQ on Al Maryah Island. Average Grade A and B office rents remained stable this quarter at AED 1,730 per sq m and AED 1,180 per sq m respectively. With limited completions during Q1, the market-wide vacancy rate remained at 25%. The Minister of Economy announced that the UAE is at an advanced stage of drafting a foreign investment law allowing 100% foreign ownership of companies operating outside free zones. Mr. Dudley commented: "The new law is intended to support innovation and technology transfer through foreign direct investment in selected sectors. The extent to which the law will impact Abu Dhabi in the short term is yet to be determined."
- Residential: Although no major deliveries took place during the first quarter of 2015, approximately 5,000 residential units are expected to enter the market by the end of 2015, dominated by the delivery of The Views (Saraya), Hydra Avenue and The Wave (Al Reem Island), C59 (Rawdhat) and Amwaj 2 (Al Raha Beach). Abu Dhabi's sales prices for residential units (apartments and villas) have remained stable during Q1 at approximately AED16,000 per sq m. Rents for prime 2 bedroom apartments continued to increase this quarter given the limited supply in the market registering a 4% increase to reach approximately AED 163,000 p.a. Mr. Dudley commented: "We expect there to be a reduction in government spending this year due to the recent decline in oil prices – which will slow down the annual demand growth rate. We expect this to be a slowdown in annual growth rather than the government putting the brakes on – employment creation and residential demand growth will continue to be sustained from projects commenced while oil prices were high. Given a current shortage of quality housing, we expect rental growth to continue, but at single-digit growth rates, rather than the double-digit rates we saw from 2013 to 2014. While the residential rental market is linked to the overall supply–demand balance, the sales market is driven more by sentiment and consequently is more sensitive to the recent decline in oil prices and equities markets. After two years of 25% annual growth, average prime residential prices have remained flat since Q4 2014 – principally due to the recent decline in oil prices, equities markets and investor sentiment."
- Retail: Abu Dhabi's retail market remained largely stable during Q1. No major deliveries took place, keeping the total retail supply at 2.6 million sq m of retail GLA. About 87,000 sq m of retail GLA is expected to enter the market by the end of 2015, largely as non-mall retail within mixed-use developments. Average line store rents within well-located malls have remained stable at AED 3,000 per sq m p.a. (Abu Dhabi Island) and AED 1,860 per sq m p.a. (off Island). Vacancies remain minimal within established regional and super regional malls. Mr. Dudley commented: "Retail growth has also remained stable, with no major supply completions in Q1 and limited completions scheduled for the rest of 2015 and 2016. Yas Mall, which has been well received by consumers and retailers, has completed its first full quarter of trading. A number of super regional malls are scheduled to enter the market from 2018 which will substantially increase Abu Dhabi's retail supply in the medium term. The future outlook for retail is positive as consumer demand continues to increase from population, employment and tourism growth."
- Hotels: Despite the heavy competition in the market, ADR levels increased for the first time since 2010 to reach approximately USD 169, reflecting an increase of 12% in YT February 2015. Occupancy rates witnessed a far lower rate of growth, reaching 77% in the first two months of 2015, just one percentage point higher than 2014. The combined growth of improved ADR levels and occupancy rates pushed the RevPAR up by 14%, to reach approximately USD 132. Two major openings occurred during Q1 – Tryp by Wyndham (146 keys) and the Swiss-Belhotel Corniche (189 keys). Additionally, 500 keys were added to the serviced apartments sector with the opening of the Meera Time Residence in Saraya and Danat Residences in Danet Abu Dhabi. Mr. Dudley commented: "Over recent years, while there has been a steady increase in tourism arrivals, the positive increase in demand was largely offset by new supply coming through, impacting on performance. While we expect an additional 3,000 rooms to enter the market by the end of 2015, the pace of supply additions is now slowing down and the extensive government initiatives to boost tourism numbers continue strongly. Occupancy rates have been increasing over recent years, now reaching 77%. This quarter, we also saw a positive increase to Average Daily Rates for the first time since 2010."
Other releases of publisher
- 22.07.2015 07:31JLL appoints Head of Integrated Facilities Management for Middle East and North Africa
- 04.06.2015 08:59JLL Unveils RED, its Corporate Real Estate Data and Insights Platform
- 21.04.2015 10:37Hospitality Sector Best Performer in Stable Abu Dhabi Real Estate Market, According to JLL Q1 2015 Real Estate Market Overview


text:
What is JotForm?
JotForm is a free online form builder which helps you create online forms without writing a single line of code. No sign-up required.
At JotForm, we want to make sure that you're getting the online form builder help that you need. Our friendly customer support team is available 24/7.
We believe that if one user has a question, there could be more users who may have the same question. This is why many of our support forum threads are public and available to be searched and viewed. If you'd like help immediately, feel free to search for a similar question, or submit your question or concern.
How can I view a summary of who I sent forms to by emailAsked by sumaria on January 29, 2014 at 04:36 AM
hi there
I want to see a summary of who I sent forms to for submission (as some I emailed, has not yet submitted their response)
S van der Berg
JotForm Support
There is really no means for us to get a summary of to whom you have sent the e-mail. Perhaps you can get this data/information from within your e-mail Sent messages?
The summary that you can view on JotForm are the submissions that the form currently have.
There are multiple ways you can see this in JotForm. Please refer to the guides below
Hope this help. Please inform us if you need further assistance.


text:
The Audi S3 at Paris Motor Show
Thats how the front headlamp of the Audi S3 looks like, truly mesmerizing to the eyes !
The S3 is the pimped up version of the A3, where this baby now punches out 300hp with the century run in just 5.1 seconds. its Quattro makes it 4 wheel drive full time, with the S-Tronic transmission in place to ensure quick shifting.
I'd say the dash have gotten a bit more classier with the grey background and white numbers. for more sound enthusiasts you can add on the Bang & Olufsen sound system.


text:
The Woodland Hills Medical Clinic is inspired to consistently deliver successful urgent care to patients around the community. Located in Woodland Hills, we make high quality urgent care an option for patients regardless of what insurance plan they have. We work with numerous HMO and PPO insurance plans to ensure every patient can be accommodated at our clinic, these include Cigna.
Cigna delivers beneficial coverage for expenses accrued from medical and drug services. In addition, patients can opt to join a Cigna plan that provides coverage specific to medical expenses. The benefits of Cigna include low monthly premiums, all-inclusive Medicare benefits, and high quality doctor-patient relationships.
At the WHMC, we look forward to working with patients covered by Cigna. Our office is dedicated to providing compassionate care in a dedicated environment. Dr. Issam Khafaja is one of the most experienced doctors in providing gentle and successful urgent care. Thanks to his expertise and phenomenal team, patients continue to benefit from the passionate care at the WHMC. Our team treats medical issues such as sprains, minor cuts, flu symptoms, chest pain, spider bites, and more.
If you require immediate medical attention for a minor injury or problem, please call us or visit our walk-in clinic. We will ensure your needs are met in the most effective and prompt manner.


text:
Basicly, I read a article on Sonic Boom and why it failed (http://nintendoevery...ic-boom-launch/)
So I kinda decided to do the same with Sacred 3, a situation probaby even more fishy than Sonic Boom.
We do know that Keen Games had, untill that time, never developped a game for PC/Consoles, correct?
Well then, let's check their hiring page, from 2011 to 2013.
Up untill November of 2013, the hiring page reads:
"Currently we are looking for a Senior Gameplay Programmer to join the Sacred3 development team." etc
Bear in mind that the game was released in August of 2014.
But it was delayed. In fact, Deep Silver scheduled Sacred 3 for 2013. Perhaps Keen Games hired the people they needed for Sacred 3 development in late 2013 or early 2014.
Interestingly, Peter Thierolf, former Technical Director of Keen Games left the company in the time period between November of 2013 and April of 2014.
And now some foreshadowing from Deep Silver themselves...
Wishing Well for Sacred 3
Dear Community,
As Deep Silver confirmed today, they are now the owner of the brand "Sacred" and plan to create a Sacred 3 (working title) in the future.
This thread should collect community suggestions for Sacred 3. The ideas will be forwarded to the devs as soon as Deep Silver decides who will create the game.
What do you think, will Sacred 3 be like Sacred 2 or completely different? What would you like to have in the new game and what kind of game could you imagine?
Not much is said, other than that Deep Silver own the brand & are planning on creating S3.
*Puts tinfoil hat on*


text:
His quizzes
User hasn't taken any quizzes
Profile link:
Story about Oliver Guetta
My name is Oliver Guetta, I'm male and 28 Years old. My Sign of Zodiac is leo. I live in Novi Sad, Serbia. On Flirtic.com I've been registered for 05.01.2013 years.
If our iterests match, you can send me a message, make a gift or invite for a date.
I speak serbian. My mother tongue is serbian.
I like to listen to Selena Gomez, Kate Ryan, Nightwish, Manowar, David Guetta, PSY, Kamelot, Avantasia, Sonata Arctica, Armin Van Buuren, Disturbed, Haggard, Guns N' Roses, Marco Hietala, Helloween, Apocalyptica, Iron Maiden, Blind Guardian, Eluveitie, Megadeth, Nickelback, Stratovarius, Papa Roach, Therion, Black Eyed Peas, Linkin Park, Three Days Grace, Van Gogh, Tuomas Holopainen, Anette Olzon.
Oliver Guetta
Was online 05.04.2013
He is not a VIP user. Send him VIP as a gift »
|Aim of acquaintance:
|Yet to be answered
|Interested in:
|Native language:
|Response rate
|very low
Do not participate in Top 100. Reason:
Has no new profile pictures


text:
Well-known member
After a quick look at the code, it seems that the global used size is saved in XenForo_Application::get('options')->attachmentThumbnailDimensions
And this size is used in the attachment model and in the defered script to rebuild the thumbnails
What if i want to have different thumbail sizes?
e.g. my Gallery thumbails should be 200x200, my post thumbails only 150x150 and my cms thumbails 250x250
If the data would come from the attachment handler, it would be much easier to use different sizes for the thumbails.
You could even add the attachment handler name / content ty eas parameter to attachmentModel::getAttachmentContraints, which could return then the content type specific attachment sizes. so we wouldn't have to implement / overwrite this method for own types


text:
Quick Details
- Product Type: Trimming
- Material: glasses
- Trimming Type: Beads
- Use: Garment, Shoes
- Place of Origin: Guangdong, China (Mainland)
- Brand Name: OEM/FONIA
- Model Number: WH030
Packaging & Delivery
|Packaging Details
|PP bag/carton
|Delivery Time
|3-15 days
Specifications2011 Fashion Rhinestone mesh,rhinestone trimming, rhinestone chain, can be mixed in many different colors.
1.Swarovski/CrystalGlass/Acrylic Rhinestone with mesh and brass cup base
2.various colors and sizes available
3.custom design available...
4)Eco-friendly materials
Transaction History of the Supplier
Below is the information about the supplier's transactions conducted via Alibaba.com. If you require further details regarding the transaction data, please contact the supplier directly.
Transaction Overview
Export Markets
Transaction Details
This supplier has completedtransactions with buyers from .
Shipping Destination
Transaction Value
Transaction Date
Email to this supplier


text:
Mark Greene at Forbes Magazine nailed it earlier this month in his article the perfect loan file, which really does capture the rigor with which lenders are scrutinizing every mortgage loan application these days. In my opinion, this should be mandatory reading for every buyer in the marketplace now.
Lenders demands for proper / acceptable supporting documentation can be pretty daunting.
I see many clients with qualifying income and credit scores being driven to tears by the excruciating process. In recent weeks more than a couple have simply quit. Some are using all cash to make their deals, avoiding the hassle altogether. Others are giving up their dreams of home ownership. If I never hear a loan originator ask for (or a client complain about) "just one more thing," I will be a happy man.
Certainly understandable that lenders are being very cautious while processing their loans applications. No one wants to see loan failures given the still-too-recent market collapse - particularly where Fannie Mae and Freddie Mac are making the originators buy back problem loans. But, just the same, ill prepared consumers are at their breaking points. Inadequate loan documentation leads to delays, multiple requests for "proofs," and general levels of frustration are pretty high. Trying to keep up with the underwriters demands can be pretty severe. Many clients react poorly when told that the documentation they offered are rejected as "not good enough." Doubly so, when the loan officer "guesses" (hopefully suggests?) that they "might" be.
Smart real estate professionals, loan officers, processors, realtors, and attorneys must take extra care and effort, preparing their clients before the wage battle with the loan underwriter. Letting prospective buyers know what they are in for - early on - helps sets expectations properly, and will surely make the process a bit easier, at least less unpleasant that it currently is. Smart professionals should probably refer their clients to this article, to help their clients understand why.


text:
If you didn't have the opportunity to enjoy Tuesday's sunshine and 90-degree temperatures, don't despair. Today will be just as sunny — and about 10 degrees cooler.
But while temperatures will remain in the 80s and upper 70s over the next several days, meteorologist Andy Ervin of the National Weather Service, Davenport, said to be prepared for more active weather over the next week or so.
The threat of thunderstorms moves in tonight, and hangs around through Tuesday, he said.
"It's spring, and we'll be dealing with typical thunderstorm potential, not the cool season rains we've been having where everyone gets an inch and a half," Ervin said. "It's May turning into June, so this is right on schedule.
"Anyone who gets hit by a thunderstorm could see an inch of rain, but if you get missed, you may get another day of planting in," Ervin said of farmers scrambling to get spring crops into the ground.
He added that the system is too active to predict precisely where or when those storms will hit.
On Tuesday, the sunshine and warmth were too tempting for some people to ignore. The high temperature of 90 degrees missed breaking a six-year-old record by 3 degrees.
Debbie Healy, of Algonquin, Ill., lay in the sun near the trees at Davenport's LeClaire Park for a couple of hours.
As a pharmaceutical representative, she is in town each Monday and Tuesday and stays at the Hotel Blackhawk.
The 90-degree high coupled with a clear blue sky beckoned her outdoors after she got her work done, Healy said. "I knew in the morning I was going to take break and enjoy the day while I could," she said.
Healy wasn't alone. LeClaire Park was full of people fishing from the Mississippi River shoreline while at the Davenport Dog Park, John Baldwin of Davenport walked his Sheltie named Yoda.
"It's about time," Baldwin said. "It's an absolutely beautiful day. I like to spend as much time outside as I can."


text:
Appeal over wild camping, camp fires and litter in Poppit dunes
Learn the basics about Walking with Livestock at free event
The Romans are coming to Castell Henllys this August
Have a legendary time at the National Park's County Show marquee
Manorbier Range military heritage tour offers public rare access
Bank Holiday Weekend Warfare at Carew Castle!
Visit Carew Castle and Tidal Mill this weekend for an action-packed Bank Holiday full of battles, fabulous falcons and more! See the Collegiate of the Knights Templar 'Fight to the Death' on 27 August and enjoy a Medieval Monday on 28 August!
Coast to Coast 2017!
Coast to Coast 2017 is now available online and via the Coast to Coast app on Apple and Android devices, and outlets across Pembrokeshire. This year's edition is packed full of events, activities and features about the National Park!
Pembrokeshire: Land of Legends
Discover some of the legendary tales that have links with Pembrokeshire. They tell of huge capstones lifted into place by fairies, enormous boulders hurled down the mountainside by giants; of a fearsome lake monster and a bleeding yew tree.
See the Pembrokeshire Coast Path on Street View
You can now view the Pembrokeshire Coast Path National Trail from your computer, mobile or tablet as the world-famous walking route has been added to Google Street View.
Activities and events calendar
We have a variety of exciting activities where you can explore the National Park and appreciate its wildlife, landscape, history and culture. Our programme tries to offer something for everyone.
Home » About Us
The Pembrokeshire Coast National Park is a special place and needs careful management to look after it for everyone to enjoy, now and in the future. At the Park Authority we're charged with keeping the Park special.
Penllechwen near Whitesands Bay.
This section aims to explain the relationship between the physical environment of the The Park and The Authority's role in managing and protecting it.
Pembrokeshire Coast National Park Authority Headquarters, Llanion Park, Pembroke Dock.
The Park is a unique environment made up of many things - wildlife, habitats, farming, history, tourism, business and local communities. Our job as an Authority is to work to achieve a happy balance for all those with an interest in the Park.
It's worth remembering that National Parks are not in public ownership. Most of the land is privately owned. In fact in our case, without the foreshore lease, we own just 5.37 sq km of land - just under 1% of the area of the National Park.
So, the Authority is made up of many different parts:
And the Park is very special and very beautiful. And we want to keep it that way for future generations, which is why we're here.
There are lots of ways you can get involved. Keep an eye on the Jobs section and for ways to volunteer. You can also meet your Members. They're the representatives of Pembrokeshire County Council and Welsh Government Members who oversee the Authority's work.
Don't forget we're also on Facebook, Youtube, Flickr and Twitter! Sound like a different language? Then click on the links and find out more. Join up, become a fan, download some pictures or videos of the National Park. Just get involved!


text:
|Page (1) of 1 - 09/16/13
|email article
|print page
For more than four decades, the Man Booker Prize for Fiction has been a uniquely British award, seeking to identify the best novel by authors from Ireland and the Commonwealth. Now that distinction may end. The Sunday Times in London reported the prize committee will break with tradition and allow American authors to be eligible, beginning next year.
|Booker Prize Panel Is Said To Consider Allowing Americans To Be Eligible
Source:GrabNetworks (c). All Rights Reserved


text:
So this guy is a lot of things I'm looking for but then again I don't really want to date and he keeps proving me right. Things I like and what I've been looking for: He gave me a rose out of no where. He is a virgin, does no drugs. But there are down falls too.. He's aggressive. Like he tried to tie me up for no reason. He is an asshole at times and gives me the silent treatment. I can not take his family. He's a big mommas boy. He's really emotional. Everytime I get close to him he messes it up. Twice now. First we were talking and he had messages from other girls meeting up with them and he lied to me saying he had to clean. Then still won't admit to it. Then the second time.. Last night he said he was going home to bed. No he went to go spend time with our "friend" that can't keep her hands off of him.. I mean In some ways he's everything I'm looking for but I can't take some of the other things.. I don't know what to do.. Help someone please.
Most Helpful Guy
Doesn't sound like he's everything you're looking for. You just wrote a small paragraph of everything he does WRONG. Find someone else.11|00|0


text: Ingredients Edit ¼ cup peanut butter 2 teaspoons sweet pickles, minced Directions Edit Combine peanut butter with minced sweet pickles. Retrieved from "http://recipes.wikia.com/wiki/Sweet_Pickle_Spread?oldid=554928" Ad blocker interference detected! Wikia is a free-to-use site that makes money from advertising. We have a modified experience for viewers using ad blockers Wikia is not accessible if you've made further modifications. Remove the custom ad blocker rule(s) and the page will load as expected. Categories: Spread Recipes Peanut butter Recipes Pickle Recipes Add category Cancel Save


text:
Holy cow, so much information from BarkWorld, my brain is still on overload.
Let me start by saying I was so gld to have my husband who is city savvy with me to do the driving in the city because I would have had panic attacks.
This was my second BarkWorld, so I knew what to expect, but this was the first time I've stayed downtown Atlanta so it was entirely new to me. The last BarkWorld I attended was in Buckhead where we found and fell in love with Zesto's, which thankfully was about a 10 minute drive from downtown.
Atlanta seems to really love quick open fast food, as we were told by my sister-in-law to try The Varsity, so we had that on the way in, Zesto's the next day and Henry's Tavern as it was right across from the hotel we booked and the Loew's where the event was.
I highly recommend all three places if you are driving there, if not definitely stop by Henry's, they have Parmesan fries. *drools*
For those who have never been to downtown Atlanta, it is pricey to park there during the day and overnight, we paid $20/night to park. The valet parking at our hotel was $25.
Let's get to the conference portion of it, Thursday night was a premiere party for Lucky Puppy which is a quarterly magazine by Dogster.
Friday was the first official day of the conference and the keynote speaker was Gus Kenworthy, if you're not familiar with the name you may be familiar with the term "Sochi Dogs" from the winter Olympics in Sochi, Russia. He and his partner rescued 5 of them, unfortunately 1 of them passed while being held by the Russian government, but the rest of them are alive and happy.
Katie Capteron the Editor in Chief of HLN/CNN Digital spoke on Saturday touching on the top 10 viral animal stories, one of which was the two dogs hugging hours before being euthanized. This led to an outpouring of support and the rescue that got them, Angels Among Us was in attendance. She touched on several other stories, such as the dog whose mouth was taped shut, the vet tech who shot the feral cat with a bow & arrow, the two dogs rescued from underneath the I-5 bridge in California by Hope for Paws (who was also in attendance) and of course the #1 story which was Cecil the Lion.
She had the room crying at the injustice, clapping at those that were rescued and reminding us that if we see something online we need to post it, state how we feel and share.
My favorite keynote speaker was Shorty Rossi from Animal Planet's PitBoss. He warned everyone that we may laugh, cry or not like what he has to say at the beginning of his speech. He went into his background – how he was mistreated, how he got into trouble with the law, found that his love for animals helped him cope and when he got out he knew he didn't want to go back to doing bad, he wanted to make a difference.
It was then that he found his first pit bull. In trying to get a tv show about his production company he was approached about doing a show about his pit bulls. It was there he found the platform and audience to make a difference in these wonderful dogs lives.
He encouraged everyone to educate themselves on these "bull breeds", giving the group some surprising statistics such as: Golden Retrievers are the most likely breed to bite, 1 out of 600 pit bulls in shelters get adopted, support the rescue groups that support the dogs and most importantly you can't change everyone's mind but if you can change one person's mind, then it's worth it.
One of the questions he got from the group was how does he handle negativity on his page, his answer was simple: the first negative post, he deletes it, next negative post he deletes and blocks the user.
He stressed not to judge a breed by one dog and to use social media to make a difference.
These were the big names of some of the speakers, there were other speakers teaching how to use Periscope, SEO and more.
I did my first Periscope with Trista Polo from According to Bella after welcoming her to BarkWorld as it was her first time there and explaining some of the things to expect and look forward to.
Then I got a chance to be interviewed by Lisa Illman. I was petrified, but the chance to talk about my passion helped ease my nervousness, a little bit.
I was lucky enough to speak with Isabella Maso the owner of Isabella's Pet Shop. She's 10 and making bowties and flowers to help benefit shelter pets. I couldn't resist them and picked up two for the furry children.
I spoke to the owner of SleekEz, Kuddly.co, Tomlyn, Vetericyn, PetPages, Smitten, Paintapic.com, Lindsi Jones of Lindsi Jones Photography who volunteers at a cat rescue not too far from my hometown, I met bloggers who were just starting, pet sitters, artists, etc.
BarkWorld was a wonderful experience and they have already announced the dates for next years – October 13-15th at the Loews in Atlanta, GA.
So if you get a chance to go, if you have an Instagram, Periscope, Facebook, blog, Etsy page, a pet related business or blog, go.
It is a whirlwind of information, but you will make friends with the 4-legged and 2-legged alike.
I will be doing reviews, interviews and trying my hand at periscoping.. I did download the app and I apologize in advance as I'm not a fan of being in front of the camera, but rather behind it.


text:
Newark, New Jersey car lots with lease here, lease to own, buy here pay here finance leasing for used cars. You'll find a car you want to buy when financing autos from a car dealer with several used cars on the lot to choose from with many dealer loan options for people with bad credit or previous bankruptcy.
Auto marts with in house guaranteed approved, tote the note, 2nd chance financing in Newark, NJ find it hard to complete with our auto sales and leasing programs for people with bankruptcy, poor credit, or terrible credit. Complete online application today. Once you apply, you'll be contacted by finance manager at one of our auto outlet car centers with the max you can borrow.
Request Dealer Financing Online Today!
Get started now by filling out the form below. The process is fast, easy, and secure!
or Start By Phone (855) 769-3482
Tenafly, NJ resident Tobias is approved for a $11,000 car loan with $2000 down.
Aug 15, 2017 - 04:57 pm
Lynsey's auto loan has just been sent to a used car dealer in Greenwood Lake, NY.
Aug 15, 2017 - 09:05 pm
Chery was declined for a used car loan in Columbia, NJ based on low income.
Aug 16, 2017 - 12:22 pm
We're often asked, Can I lease a car with bad credit in Newark?. The answer is yes. Since the economy tanked a few years ago more and more car dealerships entered the lease here pay here arena. Lease to own car lots in New Jersey approve consumers directly, there is no need for a credit check or a good credit score to approve the transaction, just a job or consistent income.Leasing a car with bad credit Newark, NJThere is no minimum income or job time requirement. Payment terms are based on your pay check schedule. Monthly, bi-monthly, bi-weekly, and weekly payments are available to accommodate your income stream.
"I really enjoyed being treated as a person, not at all like the other dealership I went to. No pressure was shown. They cared about the person, not just making the sale." Matt B.
"What a great experience. Our rep was very excellent to work with. We thank you very much for working with us." Jessica K.
"Excellent service and great car. Very satisfied!" Roger P.


text:
Vanessa Getty's Purr raises $350,000
Published 4:00 am, Sunday, June 5, 2011
Purr benefit clothing sale
Fashion and fur intersected at Vanessa Getty's second Purr, a luxury clothing sale to benefit the San Francisco Bay Humane Friends, a Peninsula Humane Society auxiliary that supports a spay and neuter van performing free surgeries across the Bay Area. New and lightly worn clothing, shoes and handbags culled from more than 68 celebrities (Nicole Kidman, Portia de Rossi, Maria Bello) and designers (Dolce & Gabbana, Christian Dior, Chanel, Michael Kors, Oscar de la Renta) were sold for 30 to 70 percent off retail. More than 100 guests at the invite-only shopping spree at a private Pacific Heights home, raising $350,000 for the cause. Garments ranged from Jenni Kayne T-shirts for $50 (retail $195) to a preowned red Herve Leger dress for $275 (retail $1,000) and a new crocodile Ralph Lauren handbag, originally $17,000, priced at $12,000. "I'm here even though I can't fit into anything," said Max Boyer Glynn, several months pregnant and owner of a corgi named Brando. "My dog is my best friend." Naturally, none of the garments featured fur; Getty prefers it on living creatures.


text:
IQ Pharma Director
We currently have a vacancy for an IQ Pharma Director to join our IQ Research Team. Working across clients and therapy areas, the Director will own and lead project deliverables, overseeing all aspects of research projects. They will be responsible for building positive relationships with our clients during and beyond the duration of research projects along with establishing new client relationships
Core Job Responsibilities include but are not limited to:
- Innovate new ideas within the scope of quantitative market research to ensure Cello Health Insight continues to be a best-in-class leader while delivering value to our clients.
- Lead successful projects with support of a team of researchers from commission through to delivery.
- Generate business from your client base to contribute to the Company's overall revenue.
- Conduct research activities to help build client satisfaction.
- Organize, sometimes heavy, workload through prioritization and discussion in order to meet all deadlines.
- Seek business development opportunities with current clients and through other leads.
- Mentor and coach team members in quantitative market research best practices.
Annual average travel 10%
Competency Guidelines:
- Business development
- Strong business acumen
- Exceptional research skills
- Excellent project management
- Exemplary coaching, leadership and management skills
Minimum Recruitment Criteria:
- Bachelor's degree in any subject
8 -10 years of experience in research or professional services organization, of which:
5-6 years of Healthcare experience is essential
To apply:
Please submit your resume and salary requirements
Meet Some of Cello Health Insight's Employees
Daniel C.
Research Executive
As a research executive, Daniel spends his days managing project logistics, keeping clients updated, and conducting interviews with patients and doctors about specific therapies.
Back to top


text:
Internet Services
Domain Registration & Transfers
Do you have a domain name? Do you need one? We can help you find and register a domain name.
Already have one, great! There are some important questions we like to ask our clients to make sure they are aware about their domain names.
• Do you know if that domain name is in YOUR name?
• When is the last time you checked the registration contact information?
• Is your domain protected from unauthorized transfers?
In many cases another firm or individual registered that domain for you. Sometimes the domains are purchased in "bucket accounts" along with many other names. This is a potentially dangerous situation if your business relies heavily on your domain for web or e-mail services. Since domains are registered for at least a year if not longer, domain names usually fall under most business owner's radars until something happens that takes your site down.
Our Policy at PC's Unlimited is that every business should own their own domain. We can help you transfer your domain to an account that is held in your name. We'll also make sure your contact information is up to date and that your passwords are recorded and accounted for. We'll also let you know if you're paying too much to keep your domain name registered.
top of page
Need a reliable hosting platform? We provide basic hosting services up to dedicated virtual solutions. Multi homed and redundant power is standard at any of our data centers.
• Your own domain name: www.yourcompany.com
• Packages starting at only $8.99 per month
For more information, please call 1-610-420-1077 or email us
top of page
Exchange Hosting
PC's Unlimited introduces Microsoft's Business Productivity Suite
The benefits of enterprise email and collaboration are now available as a service (SaaS) through Microsoft's Business Productivity Suite (BPS). Microsoft Exchange 2007, Office Communications Server (OCS) 2007 and Windows SharePoint Services 3.0, all delivered as a hosted service, with no deployment effort, zero maintenance and no upfront costs. All these services are combined into one simple package, along with an award-winning control panel for 24x7 management.
Learn more about BPS and discover many ways your company will benefit.
top of page
Web Development & E-Commerce
PC's Unlimited's website designers provide professional, streamlined, clean and user-friendly websites at affordable rates. Most importantly, our designers are dedicated to working closely with clients to set and efficiently meet project goals and deadlines.
Call or write us today to learn more.


text:
Cleaning The Orchard and Other Episodes is a fan-fiction VHS/DVD Release featuring one Charmaine and Latoya episode, one The Powerpuff Girls episode, one All Grown Up episode, one Hey Arnold episode, one Thomas and Friends episode and one The New Adventures of Lara Laramie episode.
- Cleaning The Orchard (Charmaine and Latoya)
- Too Pooped To Puff (The Powerpuff Girls)
- Bad Aptitude (All Grown Up)
- The Aptitude Test (Hey Arnold)
- Percy's Promise (Thomas and Friends)
- Miss Priscilla's Big Break (The New Adventures of Lara Laramie)
- Distributed by USA Home Entertainment.
VHS/DVD Artwork
Front Cover
- Top: Charmaine and Latoya
- Bottom: Thomas and Percy from "Percy's Promise"
Back Cover
- Tommy and Dil from "Bad Aptitude"
- Harold from "The Aptitude Test"


text:
It was big news at the 2016 SEMA show when federal marshals came into the event and shut down the displays of eight companies accused of creating knock off parts. The company that was being copied, OMIX-ADA is a manufacturer of Jeep products predominantly and they are the ones who sought legal avenues to stop the offenders.
The company has released a statement regarding their action and the situation. Read it below.
Here's the statement from OMIX-ADA –
On Tuesday, November 2, the US Marshal's office conducted a search and seizure of a variety of automotive aftermarket products as part of US District Court, Civil Complaint number 2:16-cv-02527-APG-CWH, due to claimed infringements of Omix-ADA®'s patents and trademarks on products sold under the Rugged Ridge® brand. Based upon showing that it was likely to succeed on the merits of its claims for patent and trademark infringement, the district court granted Omix-ADA a restraining order against the certain parts suppliers that led to the search and seizure.
The seizures took place at the Specialty Equipment Market Association (SEMA) show and Automotive Aftermarket Products Expo(AAPEX), taking place this week in Las Vegas. Omix-ADA worked hand-in-hand with show management teams to follow clear guidelines designed to help combat infringing product at the show, which was enhanced with the court order. Counterfeit product and copyright infringement is in direct violation of SEMA and AAPEX policies and the managing parties have taken appropriate action to remove violating exhibitors from the premises.
As a dedicated exhibitor, Omix-ADA would like to thank SEMA and AAPEX management for their help and cooperation in working with the company to help protect its patent and trademark rights, as well as the aftermarket customers. Omix-ADA is also pursuing litigation with several companies selling infringing product at various online retailers.
The company views counterfeiting and infringement as a serious and widespread problem in the aftermarket industry and one that can be combatted through proper legal channels, and would encourage other members of the aftermarket industry to follow a similar path.


text:
Eleanor McEvoy
- Overview
- Biography
- Songs
- Browse by Format
- Similar Artists
|1990s 2000s
20 January 1967, Clontarf, Dublin, Eire. One of Irelands most popular singer-songwriters almost did not get to be a pop star. When McEvoy finished second level education, she studied music by day at Dublins Trinity College and worked by night in orchestra pits. Graduating from college with an honours degree in music, she was accepted to the National Symphony Orchestra of Ireland, with whom she stayed for four years. One of her earliest compositions, Only A Womans Heart, inspired the title for (and appeared on) the 1992 anthology collection A Womans Heart, which featured other Irish female artists such as Mary Black and Dolores Keane.
McEvoy signed to major label Geffen Records shortly after, and won Best New Artist in 1993 in the Irish National Entertainment Awards. In the same year, Hot Press magazine voted her Best Songwriter. Her subsequent major label work did not garner as much critical or commercial...
- MatchEleanor McEvoy
- 100%Mary Black
- 54%Maura O'Connell
- 53%Dolores Keane
- 48%Frances Black
- 34%Mary Coughlan
- 27%Shannon McNally
- 26%Eliza Gilkyson
- 26%Paul Brady


text:
|Publication number
|Publication type
|Application number
|PCT number
|Publication date
|Aug 10, 2010
|Filing date
|Feb 18, 2004
|Priority date
|Feb 19, 2003
|Fee status
|Also published as
|Publication number
|Peter R. Riehl, Sungtack Samuel Hahn
|Original Assignee
|Stellar Pharmaceuticals Inc.
|Export Citation
|BiBTeX, EndNote, RefMan
|Patent Citations (39), Non-Patent Citations (21), Referenced by (5), Classifications (12), Legal Events (9)
|External Links: USPTO, USPTO Assignment, Espacenet
This is a national phase entry under 35 U.S.C. �371 of International Patent Application PCT/CA2004/000244, filed Feb. 18, 2004, published in English as International Patent Publication WO 2004/073584 A2 on Sep. 2, 2004, which claims the benefit under 35 U.S.C. �119 of now abandoned U.S. patent application Ser. No. 10/367,970, filed Feb. 19, 2003.
The invention relates to therapeutic agents and methods useful in the treatment of cystitis, including interstitial cystitis, and related bladder conditions.
Interstitial cystitis is a bladder condition associated with discomfort and pain elicited by urinary irritants, causing urgency for, and increased frequency of, urination. Because its cause is poorly understood, the development of useful treatments has followed approaches that are largely empirical. These approaches have failed to yield more than a few useful therapeutic agents and treatments. As described by Sant and La Rock in Interstitial Cystitis, Vol. 21 (1), February 1994 at p.73, current therapies include pharmacotherapy, with intravesical use of dimethyl sulfoxide being the only therapy approved by the FDA. Still, a variety of other agents are in use to treat symptoms of interstitial cystitis, either alone or in combination with DMSO. Such agents include sodium oxychlorosene (Clorpactin), heparin, hyaluronic acid, steroid, sodium bicarbonate, silver nitrate, sodium pentosanpolysulfate, cromolyn sodium, lidocaine and doxorubicin. Many of these agents can be delivered orally, but can be most effective at the GAG surface layer of the urethelium when delivered by instillation either as monotherapy, combination therapy or sequential therapy. These agents and therapies target the bladder mucosal lining, and provide symptomatic relief of pain, frequency and urgency. Of these therapies, however, few offer relief over sustained periods.
More recently, we have described the use of chondroitin sulfate as an instilled preparation for the treatment of interstitial cystitis and related bladder conditions (see U.S. Pat. No. 6,083,933 and CA 2269260 assigned to Stellar International Inc.). As disclosed in these patents, preparations containing 80 mgs, and up to 200 mgs, of chondroitin sulfate as a 40 mL instillation provided relief from at least one symptom including frequency, pain and urgency, in patients diagnosed with cystitis. In addition, there is described a diagnostic method useful to identify responders to chondroitin sulfate therapy or therapy with other cystitis treatments. In this approach, patient candidates first receive an instilled dose of an irritant such as potassium chloride, and responders are then identified as those patients experiencing relief from the irritant-elicited symptoms upon instillation of the chondroitin sulfate or other therapeutic. For use in such therapy, Stellar International Inc., of London, Ontario, Canada markets the product Uracyst-S™, which is a treatment kit comprising a vial containing 80 mgs of chondroitin sulfate in 40 mL aqueous vehicle (0.2%), and the product Uracyst-S™-Concentrate providing a vial containing 200 mgs of chondroitin in a 10 mL vehicle (2.0%). Results of a study using Uracyst™-S are reported by Steinhoff et al in Can. J. Urol., Feb. 9, 2002 (1):1454-58.
There is a continuing need to provide, on a cost-effective basis, agents and therapies that are useful to treat cystitis, including interstitial cystitis and related conditions of the bladder and urinary tract that result from an eroded mucosal lining. It is accordingly an object of the present invention to provide such a therapy.
It has now been found that patients suffering from cystitis and related conditions of the bladder and urinary tract respond more rapidly to treatment with chondroitin sulfate when the instilled dose of chondroitin sulfate is increased above 200 mg. It had been assumed that a dose approaching 200 mg was sufficient to saturate the bladder lining and hence deposit, or adsorb, sufficient chondroitin sulfate to protect all available sites of bladder lining erosion. However, it has now surprisingly been found that a more rapid relief from cystitis symptoms can be realized when the instilled dose of chondroitin sulfate is increased, beyond 200 mgs. In addition, it has been found that administration of higher dose chondroitin sulfate provides relief in patients in whom the cystitis is so severe as to be virtually refractory to other conventional forms of cystitis therapy.
Thus, in accordance with one aspect of the invention, there is provided a method for treating a patient afflicted with cystitis or a related condition of the bladder or urinary tract, the method comprising the step of delivering to the patient by instillation a pharmaceutical composition comprising chondroitin sulfate in a unit dose of at least 250 mgs, preferably at least 300 mgs, more preferably at least 350 mgs and most preferably at least 400 mgs. Similarly, the present invention provides for the use of chondroitin sulfate in the preparation of a medicament comprising at least 250 mgs of chondroitin sulfate for the treatment of cystitis and related conditions of the bladder or urinary tract.
In other aspects of the invention, there is provided a pharmaceutical composition adapted for delivery to a patient by instillation, the composition comprising chondroitin sulfate at a unit dose of at least 250 mgs, and an aqueous vehicle therefor. In embodiments of the invention, compositions effective to treat cystitis include sterile, aqueous compositions comprising:
(1) a unit dose of highly purified grade chondroitin sulfate of at least 250 mgs, e.g., in the range from 250 mgs to saturation, and
(2) a pharmaceutically acceptable aqueous carrier, in a volume that is patient-tolerated and sufficient for exposing the bladder surface area to be treated.
In a particular embodiment of the invention, there is provided a pharmaceutical composition adapted for instillation, the composition comprising chondroitin sulfate in a unit dose of from 250 to 1200 mgs, and from 10 to 100 mL of an aqueous vehicle. In a more specific embodiment, the composition comprises 400 mgs of chondroitin sulfate in 20 mL of an aqueous vehicle, preferably phosphate buffered saline. In a very specific embodiment, there is provided a sterile chondroitin sulfate solution adapted for instillation, the solution consisting essentially of, and preferably consisting only of, 400 mgs of chondroitin sulfate and 20 mL of an aqueous buffer, preferably phosphate buffered saline.
Other aspects of the invention and embodiments thereof are now described in greater detail hereinafter, with reference to the accompanying drawing, in which:
The compositions and methods of the present invention are useful in the treatment and assessment of various forms of cystitis as they occur particularly in the bladder, but also as they occur in the urinary tract including the urethra and those other mucosal surfaces that are exposed to treatment by the vesicular instillation route of administration. By this route, a sterile catheter is placed into the bladder through the urethra, and the treatment solution fed through the catheter. The solution is then held in the bladder for at least 30 minutes or longer before voiding. The forms of cystitis that can be treated include particularly interstitial cystitis and those other forms of cystitis and related bladder conditions that respond to an enhancement of mucosal integrity and barrier function that is believed to result when the present chondroitin sulfate treatment is used. These include radiation-induced cystitis, chemical-induced cystitis, e.g., resulting from chemotherapy and hemorrhagic cystitis, as well as, more generally, GAG-deficient forms of cystitis and GAG-deficiency resulting from chronic urinary tract infection.
Cystitis-related conditions are revealed using an established potassium test, in which a 3.0% KCl solution is instilled into the bladder of the patient candidate. A response to the potassium solution with symptoms characteristic of cystitis indicates GAG deficiency in the bladder lining, suggesting that the patient has either cystitis or a condition related thereto by GAG-deficiency, and identifies the patient as a candidate for chondroitin sulfate therapy.
For use in treating interstitial cystitis and these related conditions, the present invention exploits chondroitin sulfate which is an acidic mucopolysaccharide and is one of the glycosaminoglycans (GAGs). Its repeating disaccharide unit is made of glucuronic acid and galactosamine with one sulfate group in a B (1-3′) linkage, i.e. N-acetyl galactosamine sulfate. This disaccharide unit is polymerized in B (1-4′) linkage.
Chondroitin sulfate (CS) is available in a number of mono-sulfated forms, varying according to specific chemical composition usually as related to extraction source, chain length usually as related to processing techniques, degree of sulfation, etc. For use in the present invention, the CS is desirably in pyrogen free form and is highly purified, thus yielding an "injectable grade" of material having the qualities required for human use by the various regulating agencies. Such material is available from a variety of commercial sources, and the present literature is replete with descriptions of methods suitable for producing such material. In embodiments of the invention, the CS is within the molecular size range of from about 1,000 Daltons to about 75,000 Daltons, for example from about 10,000 Daltons to about 40,000 Daltons. A suitable natural source for CS within this size range is soft connective tissue, such as cartilage.
In a specific embodiment, the CS starting material is obtained from either porcine or bovine cartilage and subsequently refined by established methods to yield the desired injectable grade and molecular size fractionated CS. Alternatively, it will be appreciated that the CS can be obtained from other sources, including synthetic routes, or can be blended to combine synthetic and natural CS forms into the desired composition. Desirably, but not essentially, the CS comprises the A-form and C-form of CS, in a blend of form 3:1 to 1:3 on a molar basis, e.g., about 1:1.
It will be understood that the CS typically is in salt form, and in accordance with embodiments of the invention, is in the sodium salt form.
For use, the CS is formulated as a sterile, aqueous solution. The formulation is desirably adapted for single dose administration, although it will be appreciated that a multi-dose formulation may be utilized to treat a number of patients.
In accordance with the present invention, the unit dose of CS administered to the patient is at least 250 mgs. More desirably, the unit dose of CS is at least 300 mgs. Preferably, the unit dose is at least 350 mgs. More preferably, the unit dose is at least 400 mgs. The upper end of the acceptable unit dose is capped, in theory, only by the solubility of the given type of CS in the chosen aqueous vehicle, and by the volume of that vehicle used in therapy. At room temperature and in sterile, distilled water, the solubility of CS approaches 50%. Thus, the upper limit of the CS unit dose can be 500 mgs/mL of vehicle. In accordance with the present invention, the unit dose of CS is desirably formulated in a solution volume that is sufficient to expose the bladder surface to be treated, and is at least tolerable and more desirably comfortable for the patient. The upper limit for such volumes lies below the volume causing hydrodistention, which is about 250 mL in some patients. For adult patients, solution volumes are suitably from about 5 mL or 10 mL up to about 100 mL, e.g. up to about 75 mL, and preferably up to about 50 mL. In a specific embodiment of the invention, a solution volume of about 40 mL is utilized. Accordingly, the upper limit of the unit dose of CS administrable to the patient at this volume can approach 20,000 mgs.
In embodiments of the present invention, the unit dose of CS administered to the patient lies suitably within the range from 250-1,200 mgs, desirably within the range from 300-800 mgs, preferably in the range from 350-600 mgs, and more preferably in the range from 375-500 mgs. In a specific embodiment, the CS is formulated in a unit dose of 400 mgs.
As vehicle for such solutions, there may be employed sterile water, saline or buffered saline. The saline vehicle is particularly useful, and in embodiments of the invention, the vehicle is 0.9% saline. Alternatively, phosphate buffered saline vehicles may be used. In a specific embodiment, the aqueous vehicle is simply sterile water for injection.
The concentration of CS within the solution will of course vary in accordance with the amount of CS formulated and the solution volume employed. CS is relatively soluble in aqueous vehicles, and a wide range of concentrations may therefore be formulated. In embodiments of the invention, the CS concentration lies within the range from 0.1 mg/mL to 100 mg/mL, preferably 1.0 mg/mL to 50 mg/mL. In a specific embodiment of the invention, the formulation has a CS concentration of about 15-25 mg/mL, e.g., 20 mg/mL. In a particular specific embodiment of the invention, the formulation achieves this concentration by providing a formulation containing 400 mgs of CS in a 20 mL volume of phosphate buffered saline.
In a specific embodiment of the invention, the sterile chondroin sulfate solution consists of 400 mgs chondroitin sulfate, and 20 mL of aqueous vehicle, such as sterile water, saline or phosphate buffered saline.
Formulation of the CS will of course be performed in a manner established in the pharmaceutical art. Unit or single doses can be produced simply by metering the unit dose of CS, say 400 mgs, into a vial which then receives 20 mL of vehicle or diluent, under aseptic filling conditions. Alternatively, such a formulation can be prepared by combining commercially available formulations, such as the Uracyst-S-Concentrate, e.g., by combining two 200 mg/10 mL solutions.
In use, the CS composition is administered by instillation or like method that directs the composition to the luminal (mucosal) surface of the affected bladder or associated surface of a patient having the symptoms of cystitis and particularly GAG-deficient cystitis including chemical- and radiation-induced cystitis, hemorrhagic cystitis and, in accordance with a preferred embodiment of the invention, interstitial cystitis. In addition to IC patients, such treatment can be useful, as noted, for "related bladder conditions", i.e., for those patients having an erosion of either the bladder lining or the lining of the urethra or ureters which is sufficiently severe to cause pain or discomfort when chemical irritants are present in the urine. Such related conditions include urinary tract GAG-deficiency resulting from chronic urinary tract infection. With each treatment, the composition is instilled, for instance as a 20 mg/mL dose of CS in a buffer volume of 20 mL, after any residual urine has been removed. The patient then retains the solution for a period desirably of not less than 30 minutes. In a typical treatment regimen, weekly or biweekly treatments are performed for about 6 weeks, and then monthly treatments are performed thereafter until symptoms are relieved. Some patients may benefit from up to 6 weekly instillations, then instillations once monthly or bimonthly thereafter depending on their symptomatic response. Maintenance dosing can be performed using doses of CS that are reduced, e.g., to 200 mgs, if patient symptoms so indicate.
As noted in the examples, patients treated in the manner just described have responded well, by indicating that symptoms of pain, urgency and/or frequency have subsided. The present success with "high dose" chondroitin sulfate is both a surprising and significant result, given, on the one hand, that chondroitin sulfate is both a commercially available and relatively inexpensive agent and, on the other hand, that so few agents tested for IC are found to provide actual benefit to the patient. Patients treated with the high dose chondroitin sulfate responded very rapidly to treatment. Moreover, the success seen in the examples herein provided has been achieved in patients having severe cystitis symptoms who were otherwise refractory to treatment with other available therapies.
It will be appreciated that the present high dose CS therapy can be utilized either as a monotherapy or in combination with other available cystitis treatments. Such known cystitis therapies include those delivered by instillation, such as DMSO, heparin, pentosanpolysulfate and hyaluronic acid. As noted hereinabove, such agents should be administered in a volume sufficient to bathe the bladder lining with an amount of the agent determined to be suitable for investigating a therapeutic effect.
For use in the therapeutic method of the present invention, there is further provided by the present invention a kit comprising, in combination,
(1) a first sterile solution comprising chondroitin sulfate at a unit dose of at least 250 mgs and an aqueous vehicle; and
(2) printed instructions teaching the use thereof in accordance with the present treatment method.
Such a kit may take the form of a box or other package in which the sterile solution is provided as a ready-to-use solution, having the concentration and unit dose described hereinabove. The printed instructions will convey to the end-user the methodology of the present invention. That methodology is exemplified below.
The following describes the treatment of interstitial cystitis patients in a clinical setting.
For use in treatment, chondroitin sulfate, as the sodium salt, was purchased as non-pyrogenic and highly purified grade. The CS was obtained from bovine cartilage to control its purity and composition of chondroitin sulfate in terms of its isomers A/C (60:40) and carboxyl/O-sulfate ratio (about 0.95), with other specifications being the following:
Appearance: white to slightly off-white highly hygroscopic solid powder
Purity (anhydrous basis): >98.0%
pH in 1% water: 5.5-7.5
Specific rotation (4% water): −20 to −30 degrees
Nitrogen (anhydrous basis): 2.5-3.5%
Sulfur (anhydrous basis): 5.0-7.0%
Sulfate ash (anhydrous basis): 21-29%
Heavy metals: <20 ppm
Chloride: <0.1%
Proteins (anhydrous basis): <1.0%
Pyrogen: pyrogen free
Average Molecular Weight: 10,000-40,000 Daltons
This CS is formulated as a 20.0 mg/mL solution, by blending, the following ingredients:
Formula Quantity
(per mL)
Na Chondroitin Sulfate (as anhydrous)
Sod. Chloride, USP
Dibasic Sodium Phosphate 7H2O, USP
Monobasic Sodium Phosphate 2H2O, USP
Sterile Water for Injection., USP OR
to Volume
Sterile Water for Irrigation USP QS
For compounding, about 20 mL of water for injection, USP, is collected, and the required amount (20 times the amounts noted above per mL of formula to make a 2% solution) of Sodium Chloride is added and mixed until completely dissolved (a minimum of 15 minutes). The required amount of monobasic and dibasic Sodium Phosphate is then added and mixed until completely dissolved (a minimum of 15 minutes). Then, the required amount of Sodium Chondroitin Sulfate, is added and mixed until completely dissolved (a minimum of 4 hours for hydration). If necessary the pH is adjusted to 7.2 0.1 with IN Sodium Hydroxide in WFI, USP or 1 N Phosphoric Acid in WFI, USP. Then, add sufficient quantity to final volume with sterile water for injection, USP and mix thoroughly. It will be appreciated that this method is also suitable for producing different unit doses of CS, simply by altering the volume of buffer and/or by altering the amount of CS and other noted ingredients. Thus, by this methodology, there are provided such CS formulations as 10-40 mL, e.g., 20 mL, formulations containing 250, 300, 350, 400, 600, 800, 1,000 and 1,200 mgs of CS.
The formulation can further comprise a preservative. In a specific embodiment, the preservative is benzyl alcohol or parabens, e.g., methylparaben, propylparaben and butylparaben and mixtures. For instance, the preservative can be 1.5% w/v benzyl alcohol. In a preferred embodiment, the formulation is adapted as a unit dose, and the preservative is accordingly not essential. Thus, in a specific embodiment, the formulation is essentially free from preservative, and other additives, and consists of aqueous vehicle, e.g. 20 mL, and the chondroitin sulfate, e.g., 400 mgs.
The compounded solution (2% or otherwise) is then sterile filled as 10-40 mL, e.g., 20 mL, aliquots into 50 mL, molded Flint I type vials previously sterilized at 250� C. for 180 minutes, and stoppered using 100% synthetic rubber stoppers of the 20 mm type. The vials are then labeled as sterile sodium chondroitin sulfate solution. Hereinafter, the 400 mg/20 mL formulations, 2.0%, are referred to as "Uracyst-S-400" formulations.
In the alternative, patients received two doses of Uracyst-S-Concentrate (200 mgs/10 mL, purchased from Stellar Healthcare of London, Ontario, Canada) per instillation, to deliver 400 mgs of CS in 20 mL of the buffer.
The CS so formulated (400 mg/20 mL [2.0% w/v], Uracyst-S-400) was assessed, in a pilot study with six patients diagnosed with interstitial cystitis. All patients had positive potassium tests, negative cystoscopies and symptoms of daytime frequency of +8 and/or bladder pain. All patients completed an Oleary Sant questionnaire once a week. The three patients receiving twice weekly treatment completed the Oleary Sant once a week also. The potassium test was performed using the product "Solution K" sold by Stellar Healthcare in London, Ontario, Canada i.e., by instilling a 3.0% KCl solution in the manner instructed by that supplier.
Patient #1 was referred from another urologist seeking a second opinion regarding a cystectomy. She complained of unremitting and severe bladder pain. She had not found success with any treatment. She received six weekly treatments of intravesical Uracyst-S-400. There was no improvement in her symptom/problem score, and she was referred back to the urologist for cystectomy.
Patient #2 presented with long standing interstitial cystitis (IC) and has had some success with previous treatment. She entered the pilot study due to a prolonged and painful flare-up of her IC. She received intravesical instillations of Uracyst-S-400 on Monday and Thursday for six consecutive weeks. Her symptom and problem score improved each week. She was pain free at week 6.
Patient #3 also presented with long standing IC. She complained of frequent painful flare-ups that include severe frequency and nocturia. The patient was also diagnosed with irritable bowel syndrome (IBS). She was treated with Uracyst-S-400 twice weekly (Mondays and Thursdays) for seven weeks. Although two dosing intervals were missed, the patient's problem and symptom scores each dropped five points by the end of the therapy. The patient continues on Uracyst-S-200 mg therapy q2weeks and will soon be placed on once monthly instillations at this dose. Her symptoms continue to improve.
Patient #4 was referred for flare-up of IC. She had been on oral treatment for 10 years and experienced frequent flare-ups. She was treated once weekly with Uracyst-S-400 for six weeks. Each of her problem and pain scores decreased/improved by 10 points. The patient continues with monthly instillations of Uracyst-S-200.
Patient #5 was referred for bladder pain and frequency, and presents also with fibromyalgia and osteoarthritis and is on medication for these conditions. She was treated with weekly instillations of Uracyst-S 400 for six consecutive weeks. The symptom score improved by 5 points and the problem score by one point. The treatment improved her bladder pain but did not improve her frequency, so the problem score does not reflect that improvement.
Patient #6 has long standing IC, fibromyalgia, emotional stresses, pelvic pain which may or may not be upregulation from her IC. She is on many medications including morphine for pain. She was initially started on weekly instillations and then switched to twice weekly after the first week. She received Uracyst-S 400 twice weekly for six weeks for a total treatment time of 7 weeks. Although symptom and problem scores were somewhat equivocal owing largely to stresses raised by her other conditions, some improvement was noted. Treatment continues every two weeks with Uracyst-S 200, and will soon be reduced to once monthly dosing.
Thus, six patients with known Interstitial Cystitis were instilled intravesically with Uracyst-S 400 (400 mg in 20 mL phosphate buffer saline) either weekly or twice weekly for 6 weeks. Four of the patients were refractory to other forms of treatment, one patient was in a flare-up while on Elmiron�, and one was new to treatment. Three of the four refractory patients were instilled twice weekly with URACYST-S 400 mg.
There were no side affects that could be associated with the instillation of the solution. One patient complained of feeling worse after the first instillation but did not want to stop the treatment—after switching to a self-lubricating catheter; there were no further complaints of feeling worse. One patient stated she had a 10 minute total body flush one hour post instillation on the first two instillations; this did not occur on subsequent instillations. There appears to be a shorter time to improvement with the 400 mg Uracyst-S has thus demonstrated that it provides faster relief of problems and symptoms of IC patients. Three of the refractory patients had mild to significant improvement. The two non refractory patients showed improvement in the six weeks of instillation.
The improvements in voiding and pain seen in this patient population are graphed in
It will thus be appreciated that high dose chondroitin sulfate provides a therapy useful in the treatment of patients suffering from cystitis, and is particularly useful for the treatment of patients presenting with severe or long-term interstitial cystitis and related forms of GAG-deficient cystitis.
|Cited Patent
|Filing date
|Publication date
|Jan 15, 1988
|Jun 20, 1989
|Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo
|Method for inhibiting infection of human T-cells
|Feb 2, 1988
|Dec 12, 1989
|Lindstrom Richard L
|Additive for irrigation solution or surgical solution
|Apr 21, 1986
|Jul 24, 1990
|Choay, S.A.
|Method for carrying out the organic synthesis of oligosaccharides containing galactosamine-uronic acid patterns, new oligosaccharides obtained and biological applications thereof
|Nov 16, 1987
|Jan 22, 1991
|Mediolanum Farmaceutici Spl
|Process for the controlled preparation of low molecular weight glucosaminoglycans
|May 2, 1989
|Apr 16, 1991
|Crinos Industria Farmacobiologica S.P.A.
|Sulfoamino derivatives of chondroitin sulfates of dermatan sulfate and of hyaluronic acid and their pharmacological properties
|Sep 26, 1989
|Aug 6, 1991
|Saliba Jr Michael J
|Medical application for heparin and related molecules
|Feb 14, 1990
|Oct 27, 1992
|The United States Government As Represented By The Secretary, Dhhs
|Use of suramin to treat rheumatologic diseases
|Mar 16, 1992
|Jul 30, 1996
|The Australian National University
|Sulphated polysaccharides having anti-metastatic and/or anti-inflammatory activity
|Jul 21, 1993
|Feb 25, 1997
|Crinos Industria Farmacobiologica Spa
|Use of polysaccharides in acute peripheral neuropathies
|Apr 19, 1999
|Jul 4, 2000
|Stellar International Inc.
|Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
|Apr 24, 1996
|Nov 7, 2000
|The Australian National University
|Preparation and use of sulfated oligosaccharides
|Dec 30, 1999
|Jul 9, 2002
|Gliatech, Inc.
|Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
|Dec 23, 1996
|Dec 10, 2002
|Nutramax Laboratories, Inc.
|Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue
|Sep 19, 1996
|Mar 25, 2003
|Seikagaku Corporation
|Anti-inflammatory agent
|Apr 8, 1998
|Feb 10, 2004
|Theoharis C. Theoharides
|Method of treating mast cell activation-induced diseases with a proteoglycan
|May 16, 2003
|Dec 18, 2003
|Theoharides Theoharis C.
|Compositions for treatment of diseases arising from secretion of mast cell biochemicals
|Feb 19, 2003
|Aug 19, 2004
|Hahn Sungtack Samuel
|Cystitis treatment with high dose chondroitin sulfate
|Mar 24, 1982
|May 28, 1985
|David B. Soll
|Protection of cells
|Aug 3, 1984
|Aug 23, 1988
|Allison S. Chang
|Chondroitin sulfate/sodium hyaluronate compositions
|Jun 29, 1990
|Dec 30, 1991
|Daniel Bar-Shalom
|Uses of sulphated sugars
|Jul 2, 1991
|Jan 4, 1992
|Heino Diringer
|Long-term prophylaxis against diseases caused by viruses or by unconventional viruses
|Jan 29, 1992
|Aug 13, 1992
|Clarence C. Lee
|Injectable medical lubricating fluid composition and method of use
|Apr 22, 1992
|Nov 18, 1992
|Egidio Marchi
|Glycosaminoglycans in the treatment of diabetic nephropathy and diabetic neuropathy
|Oct 26, 1990
|Apr 28, 1991
|Diane M. Snow
|Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
|Aug 13, 1992
|Feb 24, 1993
|Maurice Petitou
|Sulfated glycosaminoglycanoid derivatives
|Nov 16, 1992
|May 16, 1993
|Glen M. Hartung
|Method for treatment of acute and chronic painful arthropathic conditions in human and other mammals
|Jun 29, 1993
|Jan 6, 1994
|Howard K. Shapiro
|Compositions and use of pharmaceutical compositions in the treatment of symptoms of disorders related to chronic inflammatory diseases and etiologically related symptomology
|Jul 15, 1994
|Jan 17, 1995
|Paquita E. Barnum
|Cation-complexed polysaccharides
|Aug 17, 1994
|Feb 27, 1995
|Richard A. Berg
|Ionically crosslinked glycosaminoglycan gels for soft tissue augmentation and drug delivery
|May 11, 1995
|Nov 23, 1995
|Howard K. Shapiro
|Compositions for treatment of chronic inflammatory diseases
|Feb 14, 1996
|Aug 22, 1996
|Bioniche Inc.
|Use of Hyaluronic Acid for the Treatment of Interstitial Cystitis
|Sep 30, 1997
|Apr 9, 1998
|Sumitomo Pharmaceuticals Co., Ltd.
|Sustained release formulation
|Apr 15, 1993
|Feb 1, 1995
|Seikagaku Corporation
|Platinum complex and antineoplastic agent
|Nov 16, 1992
|May 27, 1993
|Arthro Research And Development Corporation
|Method for treatment of acute and chronic painful arthropathic conditions in human and other mammals
|Apr 15, 1993
|Oct 28, 1993
|Seikagaku Corporation
|Platinum complex and antineoplastic agent
|Jun 29, 1993
|Jan 6, 1994
|Shapiro Howard K
|Composition containing amine and amine-related derivatives of benzoic acid and uses therefor including treating inflammatory diseases
|Jul 31, 2001
|Feb 7, 2002
|Dermal Research Laboratories, Inc.
|Methods of preventing or treating diseases and conditions using complex carbohydrates
|Oct 16, 2003
|Apr 29, 2004
|Marcum Frank D
|Treatment for traumatic synovitis and damaged articular cartilage
|Feb 18, 2004
|Sep 2, 2004
|Stellar International Inc.
|Cystitis treatment with high dose chondroitin sulfate
|#Conte et al., Metabolic Fate of Exogenous Chondroitin Sulfate in Man Arzneim-Forsch./Drug Res. 41(II)7, 1991, pp. 768-772.
|#Hurst et al., A Deficit of Chondroitin Sulfate Proteoglycans on the Bladder Uroepithelium in Interstitial Cystitis, Urology, 1996, pp. 817-821, vol. 48.
|#Hurst et al., A Deficit of Proteoglycans on the Bladder Uroepithelium in Interstitial Cystitis, European Urology Supplements, Official Journal of the European Association of Urology, 2003, pp. 10-13, vol. 2.
|#Hurst et al., Functional and Structural Characteristics of the Glycosaminoglycans of the Bladder Luminal Lining, J. Urol., 1987, pp. 433-437, vol. 138.
|#Kurth et al., The Interstitial Cystitis Syndrome: Intravesical and Oral Treatment, European Urology Supplements, 2003, pp. 2-9, vol. 2.
|#Mast cells may account for success of GAG layer treatments, by editor Norman Bauman, [online] [retrieved Jan. 15, 1999] www.ichelp.com.
|#Medical Device License Homologation d'un instrument medical.
|#Parsons et al., The Role of Urinary Potassium in the Pathogenesis and Diagnosis of Interstitial Cystitis, J. Urol., 1998, pp. 1862-1867, vol. 159.
|#Sant & Larock, Standard Intravesical Therapies for Interstitial Cystitis, in Urologic Clinics of North America, Feb. 1994, pp. 73-83, vol. 21, No. 1.
|#Schick, Interstitial Cystitis: Diagnosis and Treatment, Journal of CME, Aug. 1998, pp. 55-66.
|#Sorensen, Chondroitin Sulphate in the Treatment of Interstitial Cystitis and Chronic Inflammatory Disease of the Urinary Bladder, European Urology Supplements, 2003, pp. 14-16, vol. 2.
|#Steinhoff et al., The efficacy of chondroitin sulfate 0.2% in treating interstitial cystitis, The Canadian Journal of Urology, Feb. 2002, pp. 1454-1458, vol. 9, No. 1.
|#Steinhoff, The Efficacy of Chrondroitin Sulphate in Treating Interstitial Cystitis, European Urology Supplements, 2003, pp. 14-16, vol. 2.
|Hauser et al., Abnormal Expression of Differentiation Related Proteins and Proteoglycan Core Proteins in the Urothelium of Patients with Interstitial Cystitis, The Journal of Urology, Feb. 2008, pp. 764-769, vol. 179.
|Hurst et al., A Deficit of Chondroitin Sulfate Proteoglycans on the Bladder Uroepithelium in Interstitial Cystitis, Urology. 1996, pp. 817-821, vol. 48.
|Hurst et al., Bladder Defense Molecules, Urothelial Differentiation, Urinary Biomarkers, and Interstitial Cystitis. Urology. 2007, pp. 17-23, vol. 69 (Suppl 4A).
|Hurst et al., Functional and Structural Characteristics of the Glycosaminoglycans of the Bladder Luminal Surface. The Journal of Urology, Aug. 1987, pp. 433-437, vol. 138.
|Hurst et al., Identification of Proteoglycans Present at High Density on Bovine and Human Bladder Luminal Surface, The Journal of Urology, Nov. 1994, pp. 1641-1644, vol. 152.
|Hurst et al., The Role of Glycosaminoglycans in Normal Bladder Physiology and the Pathophysiology of Interstitial Cystitis, Research in Interstitial Cystitis, Chapter 11, 1997, pp. 93-100.
|PCT International Search Report, PCT/CA2004/000244, dated Dec. 13, 2004.
|Slobodov et al., Abnormal Expression of Molecular Markers for Bladder Impermeability and Differentiation in the Urothelium of Patients with Interstitial Cystitis, The Journal of Urology, Apr. 2004, pp. 1554-1558, vol. 171.
|Citing Patent
|Filing date
|Publication date
|Jul 21, 2010
|Dec 27, 2011
|Stellar Pharmaceuticals, Inc.
|Cystitis treatment with high dose chondroitin sulfate
|Nov 8, 2011
|Dec 18, 2012
|Stellar Pharmaceuticals Inc.
|Cystitis treatment with high dose chondroitin sulfate
|Dec 17, 2012
|Jul 15, 2014
|Stellar International Inc.
|Cystitis treatment with high dose chondroitin sulfate
|Jul 21, 2010
|Nov 18, 2010
|Riehl Peter R
|Cystitis treatment with high dose chondroitin sulfate
|Feb 18, 2004
|Dec 14, 2005
|Stellar International Inc.
|Cystitis treatment with high dose chondroitin sulfate
|U.S. Classification
|International Classification
|Cooperative Classification
|European Classification
|Sep 24, 2007
Owner name: STELLAR INTERNATIONAL INC., CANADA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAHN, SUNGTACK SAMUEL;RIEHL, PETER R.;REEL/FRAME:019868/0463;SIGNING DATES FROM 20030512 TO 20030516
Owner name: STELLAR PHARMACEUTICALS INC., CANADA
Free format text: MERGER;ASSIGNOR:STELLAR INTERNATIONAL INC.;REEL/FRAME:019868/0757
Effective date: 20041223
Owner name: STELLAR INTERNATIONAL INC., CANADA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAHN, SUNGTACK SAMUEL;RIEHL, PETER R.;SIGNING DATES FROM20030512 TO 20030516;REEL/FRAME:019868/0463
|Mar 8, 2011
|Certificate of correction
|May 25, 2012
Owner name: MIDCAP FUNDING III, LLC, AS AGENT, MARYLAND
Free format text: SECURITY AGREEMENT;ASSIGNORS:STELLAR PHARMACEUTICALS INC.;TRIBUTE PHARMACEUTICALS CANADA LTD.;TRIBUTE PHARMA CANADA INC.;REEL/FRAME:028275/0357
Effective date: 20120511
|Feb 21, 2013
Owner name: TRIBUTE PHARMACEUTICALS CANADA INC., CANADA
Free format text: MERGER;ASSIGNOR:STELLAR PHARMACEUTICALS INC.;REEL/FRAME:029849/0376
Effective date: 20121211
|Mar 20, 2013
Owner name: MIDCAP FUNDING III, LLC, AS AGENT, MARYLAND
Free format text: CONFIRMATION OF INTELLECTUAL PROPERTY SECURITY AGREEMENT RECORDED AT REEL 28275, FRAME 0357;ASSIGNOR:TRIBUTE PHARMACEUTICALS CANADA INC.;REEL/FRAME:030049/0126
Effective date: 20130227
|Aug 8, 2013
Owner name: SWK FUNDING LLC, TEXAS
Free format text: SECURITY AGREEMENT;ASSIGNOR:TRIBUTE PHARACEUTICALS CANADA LLC;REEL/FRAME:030988/0171
Effective date: 20130808
|Aug 27, 2013
Owner name: TRIBUTE PHARMACEUTICALS CANADA INC., CANADA
Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MIDCAP FUNDING III, LLC;REEL/FRAME:031093/0486
Effective date: 20130808
|Feb 5, 2014
|Fee payment
Year of fee payment: 4
|Feb 5, 2016
Owner name: TRIBUTE PHARMACEUTICALS CANADA, INC., CANADA
Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:SWK FUNDING LLC;REEL/FRAME:037674/0301
Effective date: 20160205


text:
Instagram: armyallen1156
I'm romantic when I have a reason to be. I love harder and fall faster than my partner, always. I can be a stone cold asshole with no feels or remorseful for my actions. I'm in love with the idea of being in love but putting in effort scares me, The unknown frightens me. But showing fear is weak in the eyes of the man. So I wait and explode one day without warning or reason, the look of confusion on her face. Can't express my feelings but I have so many, I have thoughts but my words escape me.
I'm that guy, like all guys.. That love and dream about sex. I can easily turn my emotions off in the beginning and make our meeting about only sex. Feelings for each other don't matter. Names don't even have to be exchanged. It's basic needs like animals in the wild. I have no standards, so I been told. But i try not to worry about the yesterday or tomorrow because in this moment I might be fucking.
It's not all about sex but than again it kind of is. I'm a great guy deep down on the inside. Most woman don't stay around long enough to see that side but it's there. My emotions change like the wind, fast and all over. We all have a dark side within ourselves, I just believe I have more bad than good.


text:
Find Hostels all over the World
Feung Nakorn Balcony Rooms and Cafe, HOSTEL in Bangkok Thailand.
Feung Nakorn Balcony Rooms and Cafe.
125 Trok Feung Thong, Bangkok, Thailand
Located near:
Welcome to a pleasant sanctuary in the heart of Rattanakosin Island.
The best heritages stop where you can rediscover the old Bangkok within walking distance.
" Feung Nakorn Balcony is the first boutique hotel situated on Fueang Nakhon Road.
From the past until today, this charming, classic Bangkok


text:
|Message view
|« Date » · « Thread »
|« Date » · « Thread »
|Guo Du <mrdu...@gmail.com>
|Re: Jackrabbit 3: extracting same name sibling support from the core
|Thu, 11 Feb 2010 12:14:03 GMT
On Thu, Feb 11, 2010 at 11:54 AM, Thomas Müller <firstname.lastname@example.com> wrote: > About SNS (same name siblings): what about moving that part away from > the "core"? Currently, the Jackrabbit architecture is (simplified): > > 1) API layer (JCR API, SPI API) > 2) Jackrabbit core, which knows about SNS > > After moving the SNS support, it would be something like this: > > 1) API layer (JCR API, SPI API) > 2) SNS support code, which knows about SNS, and maps SNS node names > to/from internal node names > 3) Jackrabbit core, doesn't know anything about SNS (node names must > be unique, "[" and "]" are supported within node names) > > My hope is that this would simplify the core, because it doesn't have > to deal with SNS at all. Disadvantage: there is a risk that certain > things would get a bit slower if SNS are actually used (specially if > there are lots of SNS). Is this could be an optional feature in 3.X? As JCR 2.X is out and it could raise comparability problem, right? Personally I don't like/use SNS in a navigatable content system. To be safe, I created customized node type use sameNameSiblings="false" as a base for all my nodes:) -Guo
|View raw message


text: Committee to revisit city riverfront ideas By Jim Balow July 16, 2012 Story Share CHARLESTON, W.Va. -- Mayor Danny Jones reactivated City Council's Riverfront Committee Monday, to find more ways to enjoy Charleston's two rivers -- the Kanawha and the Elk.The committee has been idle for several years after helping implement some of the proposals of the landmark 2006 riverfront master plan, which was written by Sasaki Associates.After construction of the canopy and stage and Haddad Park and the new overlook at the foot of Court Street, many people assumed the committee's work -- and the Sasaki plan -- was complete, said Councilwoman Mary Jean Davis, who was reappointed as chairwoman.But during public meetings earlier this year by consultants who are writing a new comprehensive plan and downtown redevelopment plan for the city, the riverfront was a major theme, Davis said."When we got to these meetings, people across all ages talk about the Boulevard being more convenient to walk and bicycle," she said. "It's one of those things: you sit back and think, let's get people more involved in that. Obviously you need more money."Davis had asked Jones to reactivate the committee about six months ago. But with the start of the Imagine Charleston planning process, they decided to wait, she said. The group will probably meet in October, after the consultants present their initial findings. The initial focus will be on Kanawha Boulevard, she said -- better use for bicycles, pedestrians and jogging."There's no doubt we'll look at the Elk River as well. We'll have to look at the lower [Boulevard] sidewalk, and how to extend it under the Elk River Bridge."There are a lot of creative ideas out there, and it's about time," Davis said. "It's an exciting time for the riverfront."Also Monday, council members:* Reprogrammed $100,000 of federal block grant funds originally earmarked for Chamberlain Court. Half of the money -- $50,000 -- will be used to buy and install playground equipment at the new housing units at Washington Manor.* Agreed to settle a 2008 lawsuit filed against the city by Robert W. Stack. City Attorney Paul Ellis said Stack was injured in a Jan. 3, 2007, traffic accident with a police officer. "It was our fault," Ellis said. The $38,500 settlement was reached through mediation. "The demand was over $100,000." Reach Jim Balow at firstname.lastname@example.com or 304-348-5102. Story Share Story Share Trending Now 1 Trump turns down Murray Energy coal relief proposal 2 Trump's Interior Department moves to stop mountaintop removal study 3 Charleston police officer pleads not guilty to negligent homicide 4 Casey fuming that Justice blamed wife's politics for unexpected firing 5 Despite party switch, WV GOP to oppose Justice's road bond referendum Employee transfers all but closed in Putnam schools Previous Story W.Va. in talks with three companies about crackers Next Story


text:
Table of Contents
This DataPack contains tables from VPGMarketResearch.com new report,
"2016 U.S. Drugs of Abuse POC/Decentralized Testing Market: Physician Offices, Emergency Rooms, Ambulatory Care Centers-- Supplier Shares, Sales Forecasts, Emerging Technologies, Competitive Strategies."
For pricing information on DataPack sections or individual tables, please contact Customer Service.
Get Industry Insights. Simply.
Hospitals and outpatient centers are medical facilities that provide diagnostic and medical treatment to patients with a wide range of medical conditions. Outpatient care centers offer medical care o ...
"IV equipment market is projected to grow at a CAGR of 6.2%." The IV equipment market is expected to grow at a CAGR of 6.2% from 2017 to 2022, to reach USD 13.63 billion by 2022 from USD 10.07 billion ...
This new 279-page report from VPGMarketResearch contains 58 tables, and provides a comprehensive analysis of the POC hematology and flow cytometry market, including trends, dynamics, size, growth, regulatory ...
Occupational He...
United States
United Kingdom
Cardiovascular ...
United Kingdom
United States
Reportlinker.com © Copyright 2017. All rights reserved.


text:
Exxon Mobil
The oil giant reported a sharper than expected 68% drop in third-quarter earnings as revenue fell precipitously on lower commodity prices.
After rival Symantec easily beat earnings estimates, the security software specialist merely met Wall Street forecasts for third-quarter profits.
First Solar
The solar-panel maker topped earnings estimates, but investors worried about signs of pricing erosion. One analyst downgrade followed.
As a result of its recent bailout, the Dutch financial-services company will have to sell its insurance an...


text:
We help you find a Llanarth lute tutor. Lute lessons are a great way to learn a stimulating new hobby, acquire a new skill and gain confidence with lute. Try our service to search for Llanarth lute teachers and choose which matches your needs so you can start your lute lessons in Llanarth straight away!
First Tutors: Music is the best way to discover Llanarth lute teachers in the UK, helping you find Llanarth lute tuition close to home and Llanarth teachers to help with any instrument such as piano, violin or guitar. We can help you find Llanarth lute lessons or a one-to-one Llanarth lute tutor to prepare for lute grades and develop your lute skills! We order Llanarth lute tutors local to you by their tuition charges and distance from you.
If you are a lute teacher wishing to offer lute tuition services in Llanarth or anywhere else across the UK, please register with First Tutors: Music or find out more about us here. Becoming a Llanarth lute teacher is a brilliant way to improve your own knowledge through providing lute lessons while assisting someone else, all in the Llanarth area!


text:
What is JotForm?
JotForm is a free online form builder which helps you create online forms without writing a single line of code. No sign-up required.
At JotForm, we want to make sure that you're getting the online form builder help that you need. Our friendly customer support team is available 24/7.
We believe that if one user has a question, there could be more users who may have the same question. This is why many of our support forum threads are public and available to be searched and viewed. If you'd like help immediately, feel free to search for a similar question, or submit your question or concern.
JotForm Support
Can you please confirm that you were not able to make the Auto Delete Submission work on your form?
Currently, there is indeed some issue with the auto delete app. It sometimes doesn't get triggered when it was suppose to. It is not working consistently. But it is not consistent for different user as well.
A bug thicket report had been submitted about it already.
As an alternative, you can also manually delete them for now after confirming submisison had been transferred to your Google Drive already.
We will wait for your confirmation response.
Having the same issue here. It sometimes does not trigger and I have to manually delete the submission. Has there bin a fix to the issue.
JotForm Support
One of my colleagues will be on your main thread shortly https://www.jotform.com/answers/856059. Stay in touch!